PD 173074: Selective FGFR1 Inhibitor for FGFR Signaling Pathway Inhibition

Executive Summary: PD 173074 (CAS 219580-11-7) is a selective, potent fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor with an IC50 of ~25 nM for FGFR1 in enzymatic assays [APExBIO]. It displays 1000-fold selectivity for FGFR1 over kinases such as c-Src and PDGFR [Rodriguez-Otero et al., 2011]. PD 173074 inhibits VEGFR2 at higher concentrations (IC50: 100–200 nM) and effectively reduces proliferation in FGFR-dependent cell lines. In vivo, it blocks FGF- and VEGF-driven angiogenesis with no apparent toxicity at 1–2 mg/kg/day in Swiss Webster mice. The compound is widely employed for mechanistic studies, target validation, and FGFR-targeted drug discovery.

Biological Rationale

Fibroblast growth factor receptors (FGFRs) are receptor tyrosine kinases involved in cell proliferation, survival, differentiation, and angiogenesis. Aberrant FGFR signaling contributes to oncogenesis, tumor progression, and resistance to therapy in multiple cancer types [Rodriguez-Otero et al., 2011]. Epigenetic silencing of tumor-suppressor microRNAs, such as the MIR9 family, results in upregulation of FGFR1 and downstream oncogenic pathways. Targeting FGFR1 with small molecule inhibitors like PD 173074 enables direct interrogation of these pathways and offers a route to validate FGFR1 as a therapeutic target [Related: Selective FGFR1 Inhibition for Advanced Cancer]. This article extends the mechanistic focus of previous reviews by detailing the product's selectivity and experimental benchmarks.

Mechanism of Action of PD 173074

PD 173074 is a synthetic small molecule that acts as a competitive ATP-site antagonist of FGFR tyrosine kinases. The compound binds the intracellular kinase domain of FGFR1, blocking autophosphorylation and subsequent activation of downstream signaling cascades, including MAPK and PI3K/AKT pathways. In vitro, PD 173074 inhibits FGFR1 with an IC50 of approximately 25 nM in purified protein kinase assays [APExBIO]. It reduces phosphorylation of FGFR1 substrates and suppresses proliferation in FGFR-dependent cell lines, such as those derived from acute lymphoblastic leukemia (ALL) [Rodriguez-Otero et al., 2011]. At higher concentrations (100–200 nM), PD 173074 inhibits VEGFR2, but selectivity for FGFR1 exceeds 1000-fold compared to c-Src and PDGFR. This selectivity profile enables dissection of FGFR-specific signaling in complex biological systems.

Evidence & Benchmarks

• PD 173074 inhibits FGFR1 tyrosine kinase activity with an IC50 of ~25 nM in enzymatic assays using purified human FGFR1 protein (APExBIO).
• It displays 1000-fold selectivity for FGFR1 over c-Src and PDGFR in comparative kinase profiling (APExBIO).
• In ALL cell lines, PD 173074 treatment (0.1–1 μM) decreases FGFR1 autophosphorylation and cell proliferation, and increases apoptosis (Rodriguez-Otero et al., 2011).
• In Swiss Webster mice, intraperitoneal administration at 1–2 mg/kg/day inhibits angiogenesis induced by FGF or VEGF, with no reported toxicity (APExBIO).
• Stock solutions of PD 173074 are stable for several months at -20°C in DMSO, and the compound is insoluble in water but soluble up to 26.18 mg/mL in DMSO (APExBIO).

This article clarifies practical compound selectivity and benchmarking over the scenario-driven Q&A provided by Optimizing FGFR-Dependent Assays with PD 173074.

Applications, Limits & Misconceptions

PD 173074 is primarily used in preclinical research to:

• Validate FGFR1 as a drug target in cancer models.
• Dissect FGFR-driven signaling pathways in cellular and animal systems.
• Screen for compounds or genetic perturbations that modulate FGFR1 signaling.
• Model resistance mechanisms to FGFR-targeted therapies.

For advanced translational contexts, this article updates the systems-level analysis found in PD 173074 and the Future of FGFR-Targeted Translational Research by presenting new peer-validated in vivo benchmarks.

Common Pitfalls or Misconceptions

• Non-selectivity at high concentrations: Above 1 μM, off-target inhibition of VEGFR2, c-Src, or PDGFR may occur, confounding FGFR-specific results.
• Ineffective in FGFR-independent models: PD 173074 does not inhibit proliferation in cell lines lacking FGFR1 dependence.
• Solubility limitations: The compound is insoluble in water; improper dissolution may result in precipitation and loss of bioactivity.
• Long-term solution instability: Prolonged storage of working solutions at room temperature can lead to compound degradation.
• Not suitable for clinical use: PD 173074 is for research use only and is not formulated for in-human therapeutic applications.

Workflow Integration & Parameters

PD 173074 (SKU A8253, supplied by APExBIO) is typically dissolved in DMSO (≥26.18 mg/mL) or ethanol (≥108.4 mg/mL with sonication). Stock solutions are recommended to be aliquoted and stored below -20°C for up to several months. For cell-based assays, final DMSO concentration should not exceed 0.1–0.2% to minimize cytotoxicity. In vivo, intraperitoneal dosing at 1–2 mg/kg/day is standard in mouse angiogenesis models. Solutions should be freshly prepared, and water should be avoided as a solvent due to insolubility. Analytical verification of FGFR1 pathway inhibition should include assessment of receptor autophosphorylation and downstream effectors (e.g., ERK1/2 phosphorylation) via Western blot or ELISA.

Conclusion & Outlook

PD 173074 is a reference FGFR1 tyrosine kinase inhibitor with high selectivity and reproducible activity, enabling precise mechanistic and translational research in FGFR-driven oncogenic contexts. Its robust performance in both enzymatic and animal models supports its use in target validation, assay development, and preclinical cancer research. As new FGFR-targeted therapeutics emerge, PD 173074 remains an essential control and benchmarking standard. For detailed protocols and product specifications, refer to the PD 173074 product page (SKU A8253) at APExBIO.